CONCELLENT
Board
2 directors, 2 in day-to-day management, last change in 2024Director and managing director
director since 04-06-2024
managing director appointed by deed of 04-07-2024
term until 04-06-2030
listed in the 2026 annual accounts, filed on 30-10-2026
Director and managing director
director since 04-06-2024
managing director appointed by deed of 04-07-2024
term until 04-06-2030
listed in the 2026 annual accounts, filed on 30-10-2026
Mandates through the years
2 names, the dashed line is todayJoseph Baert
Director, Managing director
Director, Managing director
Sofie Boone
Director, Managing director
Director, Managing director
LeadershipBoardRest of the term
Mandates as a list
- Joseph Baert
- Director, from 29-09-2017 to date
- Managing director, appointed by deed of 04-07-2024, still in office
- Sofie Boone
- Director, from 29-09-2017 to date
- Managing director, appointed by deed of 04-07-2024, still in office
Control
Shareholder
Equity €167.3m
Profit €14.3m in 2025 (profit €965,281 in 2024)
Checked score 96
Source: accounts SOPHARMA 2025
50%
This company
CONCELLENT
Equity €3.1m
Profit €541,863 in 2026
Capital
- Capital
- €350,000
- Shares
- 2,400
- Contribution per share
- €146
- Equity per share
- €1,311 in 2026
- Source
- deed of 04-07-2024
Articles of association
deed of 04-07-2024 (in Dutch)- Board ruleThese rules set how the board is made up, meets and takes decisions.
- At least 3 directorsTerm of at most 6 years
- Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
- Last Friday of September at 12:00
- Liquidation ruleIn a liquidation the creditors are paid first. What is left goes to the shareholders.
- “Alle verrichtingen vermeld in wet, gewone meerderheid van stemmen”